CSF3 and neutropenia: Although all patients in this study received prophylactic leukocyte therapy by the use of recombinant granulocyte colony-stimulating factor (GCFS), a few patients still experienced grade 3/4 leukocytopenia and neutropenia during NAC administration and could continue with chemotherapy without delay by receiving GCSF.